Krystal Biotech, Inc.
KRYS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711279
In the last 90 days, Krystal Biotech, Inc. insiders filed 0 open-market purchases and 3 sales; 422 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Krystal Biotech, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 194
- +9 vs. Q3 2023
- Shares held
- 24.4M
- +670.7K (+2.8%) vs. Q3 2023
- Total value
- $3.03B
- +$274.6M (+10.0%) vs. Q3 2023
- New holders
- 29
- 72 more added
- Sold out
- 20
- 66 more reduced
3 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KRYS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 422 | $11.1B |
| Q1 2026 | 368 | $7.32B |
| Q4 2025 | 334 | $7.01B |
| Q3 2025 | 284 | $4.94B |
| Q2 2025 | 275 | $3.80B |
| Q1 2025 | 299 | $4.98B |
| Q4 2024 | 264 | $4.35B |
| Q3 2024 | 283 | $5.15B |
| Q2 2024 | 245 | $5.24B |
| Q1 2024 | 234 | $4.49B |
| Q4 2023 | 194 | $3.03B |
| Q3 2023 | 188 | $2.76B |
| Q2 2023 | 183 | $2.71B |
| Q1 2023 | 160 | $1.68B |
| Q4 2022 | 154 | $1.66B |
| Q3 2022 | 148 | $1.45B |
| Q2 2022 | 137 | $1.36B |
| Q1 2022 | 135 | $1.37B |
| Q4 2021 | 140 | $1.35B |
| Q3 2021 | 113 | $850.7M |
| Q2 2021 | 113 | $1.12B |
| Q1 2021 | 113 | $1.27B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Krystal Biotech, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Trexquant Investment LP | 0 | $0 | 0.00% | −8,113−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −6,793−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −5,044−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −5,002−100.0% | Sold out |
| Summit Trail Advisors, LLC | 0 | $0 | 0.00% | −4,555−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −4,392−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −3,570−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −2,849−100.0% | Sold out |
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −2,055−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −1,400−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Bell Investment Advisors, Inc | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| International Biotechnology Trust PLC | – | – | – | – | Not filed |
| Jacob Asset Management of New York LLC | – | – | – | – | Not filed |
| Steward Financial Group LLC | – | – | – | – | Not filed |